Journal of Controlled Release · 2024 · 20 citations · 64 references
Life SciencesBiotechnologyMolecular BiologyGenetic EngineeringGenome EditingMolecular BiotechnologyCrispr-based EngineeringCrispr-cas SystemsDelivery Systems For Genome EditingGene Editing Payload DeliveryLipid-based Gene CarriersTherapeutic Genome EditingCrispr-cas Genome EditingCrispr-cas9 Genome EditingDelivery Systems For CrisprGenome Editing ValidationIn Vivo Genome EditingLipid NanoparticlesMrna Lipid NanoparticlesReporter Genes
Double pH-responsive xenopeptide carriers containing succinoyl tetraethylene pentamine (Stp) and lipo amino fatty acids (LAFs) were evaluated for CRISPR/Cas9 based genome editing. Different carrier topologies, variation of LAF/Stp ratios and LAF types as Cas9 mRNA/sgRNA polyplexes were screened in three different reporter cell lines using three different genomic targets ( Pcsk9 , eGFP, mdx exon 23). One U-shaped and three bundle (B2)-shaped lipo-xenopeptides exhibiting remarkable efficiencies were identified. Genome editing potency of top carriers were observed at sub-nanomolar EC 50 concentrations of 0.4 nM sgRNA and 0.1 nM sgRNA for the top U-shape and top B2 carriers, respectively, even after incubation in full (≥ 90%) serum. Polyplexes co-delivering Cas9 mRNA/sgRNA with a single stranded DNA template for homology directed gene editing resulted in up to 38% conversion of eGFP to BFP in reporter cells. Top carriers were formulated as polyplexes or lipid nanoparticles (LNPs) for subsequent in vivo administration. Formulations displayed long-term physicochemical and functional stability upon storage at 4 °C. Importantly, intravenous administration of polyplexes or LNPs mediated in vivo editing of the dystrophin gene, triggering mRNA exon 23 splicing modulation in dystrophin-expressing cardiac muscle, skeletal muscle and brain tissue. • pH-responsive xenopeptides for Cas9 mRNA/sgRNA formulation as polyplex or LNP. • genome editing of three different gene targets in different cell lines. • highly active in full serum, potency at amazingly low (100 pM) concentrations. • intravenous or intramuscular application for editing dystrophin exon 23 splice site. • genome modification and exon skipping in cardiac muscle, skeletal muscle and brain.
64
Easy quantitative assessment of genome editing by sequence trace decomposition
Eva K. Brinkman, Tao Chen, Mario Amendola et al. · Nucleic Acids Research · 2014 · 2.6K citations · Full text
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Haydar Frangoul, David Altshuler, Maria Domenica Cappellini et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text
Life Sciences, Genetics, Hematology +17